Quick Answer: In 2026, Aimovig costs about $931 to $1,055 per month at retail, Ajovy costs about $1,046 per month, and Emgality costs about $1,006 per month, all without insurance. Medicare Part D covers all three drugs for chronic migraine prevention subject to your plan's formulary tier, prior authorization, and step therapy rules, with total out-of-pocket spending capped at $2,100 per year across all Part D drugs. Commercially insured patients can use a manufacturer copay card to pay $15 to $49 per month, but those cards cannot be used with Medicare, Medicaid, TRICARE, or VA. Uninsured or Medicare patients at or below roughly 300% to 400% of the federal poverty level can apply to the Amgen Safety Net Foundation (Aimovig), the Teva Cares Foundation (Ajovy), or the Lilly Cares Foundation (Emgality) for free drug. No generic or biosimilar version of any of the three exists as of 2026.
Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab) are the three CGRP monoclonal antibodies approved by the FDA specifically to prevent migraine attacks. Amgen markets Aimovig, Teva markets Ajovy, and Eli Lilly markets Emgality. All three are self-injected once monthly (Ajovy also offers a quarterly triple-dose option), and all three carry retail list prices above $900 per month in 2026 because they are specialty biologics with no generic or biosimilar competition.
Novartis originally co-marketed Aimovig with Amgen in the US but exited that arrangement in 2020, leaving Amgen with full US commercial rights. Patients frequently ask which of the three drugs is cheapest or best covered, but the honest answer is that price and coverage depend far more on your specific insurance plan's formulary tier, prior authorization rules, and manufacturer copay card eligibility than on which molecule you pick. This guide breaks down the 2026 pricing, Medicare Part D rules, and the manufacturer patient assistance program for each brand side by side.
Federal drug price negotiation under the Inflation Reduction Act has not touched this class. None of the three CGRP monoclonal antibodies appeared in the first two rounds of Medicare price negotiation, so there is no negotiated Maximum Fair Price for Aimovig, Ajovy, or Emgality in 2026, and list prices remain set by the manufacturers. Patients struggling with the retail cost should compare the manufacturer patient assistance programs described below against the general Medicaid income limits and Medicare eligibility rules to see which coverage path applies to them.
What CGRP Migraine Drugs 2026 Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same cgrp migraine drugs 2026 can cost many times more at a hospital than at your local pharmacy:
2026 CGRP Migraine Drugs 2026 Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $931 - $1,055/month | Aimovig ~$931-$1,055; Ajovy ~$1,046; Emgality ~$1,006 for one pen, no insurance, 2026 list prices |
| Medicare Part D (2026) | Varies by formulary tier, capped at $2,100/year | Covered for chronic migraine prevention; prior authorization and documented step therapy are standard |
| Commercial insurance (after prior authorization) | $15 - $49/month with manufacturer copay card | Copay cards from Amgen, Teva, and Lilly lower the copay substantially for commercially insured patients only |
| Manufacturer copay card (commercial only) | Aimovig $49/mo; Ajovy $15/mo; Emgality $35/mo | Ineligible if you have Medicare, Medicaid, TRICARE, or VA benefits |
| Medicaid | $1 - $8/prescription, with prior authorization | Coverage and step-therapy rules for CGRP inhibitors vary significantly by state Medicaid formulary |
Retail prices reflect 2026 GoodRx, SingleCare, and pharmacy survey data and vary by ZIP code and dose strength. Part D costs depend on your plan's formulary tier and where you are in your benefit year.
Source: CMS Medicare Part D 2026 benefit design, GoodRx, SingleCare, manufacturer savings program pages
Why Hospitals Charge So Much
Aimovig, Ajovy, and Emgality are almost always billed through the Medicare Part D or commercial pharmacy benefit because patients self-inject them at home, not in a clinical setting. Hospital or clinic administration is uncommon and typically occurs only when a patient receives their first dose under observation to check for injection-site reactions or when a neurology infusion suite handles the injection for a homebound patient.
When one of these drugs is billed under the medical benefit (Part B or a commercial medical claim) instead of the pharmacy benefit, coding gets complicated. Ajovy has a dedicated code, J3031, and Emgality has a dedicated code, J3313, but Aimovig still bills under J3590, the generic unclassified biologics code, because CMS never assigned erenumab a permanent, drug-specific HCPCS code. An unclassified code means the payer has less built-in price transparency and the claim is more likely to be flagged for manual review or denied outright without the correct NDC attached.
Facility markups apply the same way they do for any specialty drug given in a clinical setting: acquisition cost plus pharmacy handling, nursing administration, and overhead. If you see one of these three drugs billed at two or three times the retail price on a facility bill, request the itemized charge, the NDC, and confirm the correct J-code was used before paying.
HCPCS J-Codes: What Appears on Your Bill
These J-codes apply only when a CGRP monoclonal antibody is administered in a physician's office or clinic and billed under the medical benefit rather than dispensed at a retail or mail-order pharmacy under the drug benefit.
HCPCS J-codes for CGRP Migraine Drugs 2026| Code | Description | What to look for |
|---|
| J3590 | Unclassified biologics (used for Aimovig / erenumab-aooe) | Confirm the NDC for Aimovig is attached to the claim; unclassified codes are frequently denied without it |
| J3031 | Injection, fremanezumab-vfrm, 1 mg (Ajovy) | The quarterly 675 mg dose (three 225 mg injections) should be billed as a single administration event, not three separate visits |
| J3313 | Injection, galcanezumab-gnlm, 1 mg (Emgality) | The 240 mg loading dose (two 120 mg injections) is billed once at initiation, then monthly 120 mg doses follow |
Most patients never see these codes because they fill their prescription at a pharmacy under the Part D or commercial drug benefit. The codes matter mainly for in-office administration or Part B medical claims.
Source: CMS HCPCS Level II code set, 2026
Patient Assistance Programs
Amgen, Teva, and Eli Lilly each run a two-tier assistance structure for their CGRP migraine drug: a manufacturer copay card for commercially insured patients, and a separate income-based patient assistance program (run through a related nonprofit foundation) for uninsured patients or those on Medicare.
Patient assistance programs for CGRP Migraine Drugs 2026| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Aimovig Co-Pay Card (Amgen) | As low as $49/month out-of-pocket for commercially insured patients | amgensupportplus.com/copay |
| Amgen Safety Net Foundation (Aimovig) | Free Aimovig for uninsured or Medicare patients at or below 400% of the federal poverty level | amgensafetynetfoundation.com |
| Ajovy Savings Card (Teva) | As low as $15/month for commercially insured patients, up to $3,500/year in savings | ajovy.com/savings |
| Teva Cares Foundation (Ajovy) | Free Ajovy for uninsured or Medicare patients at or below 300% of the federal poverty level | tevacares.org |
| Emgality Savings Card (Lilly) | As low as $35/month for commercially insured patients, up to $4,900/year in savings | emgality.lilly.com/savings-support |
| Lilly Cares Foundation (Emgality) | Free Emgality for uninsured patients at or below 300% of the federal poverty level | lillycares.com |
Manufacturer copay cards are barred by federal anti-kickback law (42 U.S.C. Section 1320a-7b) for anyone on Medicare, Medicaid, TRICARE, or VA benefits. If you have government insurance, apply to the matching nonprofit foundation, the Amgen Safety Net Foundation, the Teva Cares Foundation, or the Lilly Cares Foundation, instead of using a manufacturer coupon.
Source: amgensupportplus.com, amgensafetynetfoundation.com, ajovy.com, tevacares.org, emgality.lilly.com, lillycares.com
Medicare Part D
Medicare Part D covers Aimovig, Ajovy, and Emgality for chronic migraine prevention, meaning patients with 15 or more headache days per month, at least 8 of which are migraine days. Most Part D plans place all three drugs on a high specialty formulary tier and require prior authorization plus documentation that you tried and failed at least two older oral preventive medications, such as topiramate, propranolol, or amitriptyline, before approving a CGRP monoclonal antibody.
Total out-of-pocket spending across all your Part D drugs combined is capped at $2,100 for 2026 under the Inflation Reduction Act. Once you hit that cap, you pay $0 for the rest of the calendar year on covered drugs, including whichever CGRP monoclonal antibody you take. None of the three drugs has its own Medicare Maximum Fair Price because none was selected for the first two rounds of Medicare drug price negotiation, so your actual copay before hitting the cap depends entirely on your specific plan's formulary tier and cost-sharing structure.
Medicare beneficiaries who are denied coverage should ask their neurologist's office to file a formal appeal with clinical documentation of failed prior therapies. Patients enrolled in the Extra Help (Low-Income Subsidy) program pay a reduced, fixed copay for covered Part D drugs, but Extra Help enrollees are not eligible for the manufacturer's income-based patient assistance program foundations, since those programs require the applicant to be uninsured or enrolled in Medicare without full Extra Help.
Common CGRP Migraine Drugs 2026 Billing Errors
If your bill for Aimovig, Ajovy, or Emgality looks unusually high, check for these common issues before paying:
- Prior authorization missing or expired. Most plans require documentation of at least two failed oral preventives before approving a CGRP monoclonal antibody, and the authorization typically must be renewed annually.
- Manufacturer coupon not applied at the pharmacy counter even though you have commercial insurance and are eligible. Ask the pharmacist to rerun the claim with the copay card's BIN and PCN numbers.
- Ajovy's quarterly 675 mg dose (three 225 mg injections given at once) billed as three separate monthly fills, tripling your copay in a single visit instead of counting as one quarterly dispensing.
- Aimovig billed under the unclassified J3590 code without the correct NDC attached, causing an automatic claim denial that a coding correction can usually fix.
- Charged full formulary-tier cost-sharing after you already crossed the $2,100 Part D out-of-pocket cap for the calendar year.
- Wrong brand dispensed relative to the prescription. Aimovig, Ajovy, and Emgality are not interchangeable at the pharmacy; each requires its own prior authorization and its own manufacturer program, so a substitution can trigger an unexpected cash-pay charge.
Frequently Asked Questions
Is there a generic or biosimilar for Aimovig, Ajovy, or Emgality?
No. As of 2026, no generic or biosimilar version of any of the three CGRP monoclonal antibodies exists. All three are biologic drugs protected by patents and biologic exclusivity expected to last into the early 2030s. Cheaper alternatives while you wait include generic oral preventives like topiramate and propranolol, or oral gepants such as Qulipta and Nurtec ODT, which your prescriber may suggest during step therapy.
How do I apply for the Aimovig, Ajovy, or Emgality patient assistance program?
Contact the foundation that matches your drug: Amgen Safety Net Foundation for Aimovig (1-800-932-3060), Teva Cares Foundation for Ajovy (1-877-237-4881), or Lilly Cares Foundation for Emgality (1-800-545-6962). You will complete a patient application, have your prescriber sign a clinical certification, and submit proof of income and residency. Approved patients get the drug shipped free of charge, and applications are renewed annually.
Can I use the Aimovig, Ajovy, or Emgality savings card with Medicare?
No. Federal anti-kickback law bars manufacturer copay cards from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. These commercial-only manufacturer coupon programs cap copays at $15 to $49 per month for privately insured patients. Medicare beneficiaries should instead apply to the matching nonprofit foundation, which provides the drug free to income-eligible applicants.
What if my insurance denies coverage for a CGRP migraine drug?
Request the written denial reason, then have your neurologist's office file a formal appeal documenting that you already tried and failed at least two older oral preventive medications. If denied again, ask for a peer-to-peer review, then escalate to your state's external review process or Medicare's independent review process. While the appeal is pending, ask about a generic oral preventive or an oral gepant as a bridge option.
Does the IRA negotiated price apply to Aimovig, Ajovy, or Emgality?
No. None of the three CGRP monoclonal antibodies was selected for the first two rounds of Medicare price negotiation under the Inflation Reduction Act, so there is no negotiated Maximum Fair Price for any of them in 2026. Your out-of-pocket cost is governed by your Part D plan's regular formulary tier and cost-sharing rules, subject to the general $2,100 annual Part D out-of-pocket cap.
What does Aimovig, Ajovy, or Emgality cost without insurance at the pharmacy counter in 2026?
Cash retail prices in 2026 run about $931 to $1,055 per month for Aimovig, about $1,046 per month for Ajovy, and about $1,006 per month for Emgality, depending on the pharmacy and dose. A GoodRx coupon can lower Emgality to roughly $726 at CVS or Walgreens, and similar discounts apply to Aimovig and Ajovy at participating pharmacies.
Do I qualify for the manufacturer patient assistance program for these drugs?
You generally qualify if you are a US resident, have a valid prescription, and either have no prescription drug coverage or have Medicare without full Extra Help, and your household income falls at or below the foundation's threshold: 400% of the federal poverty level for the Amgen Safety Net Foundation (Aimovig), or 300% of the federal poverty level for the Teva Cares Foundation (Ajovy) and the Lilly Cares Foundation (Emgality). For a household of four in 2026, 300% FPL is $99,000 and 400% FPL is $132,000.
What is the difference between Aimovig, Ajovy, and Emgality?
All three are CGRP monoclonal antibodies for migraine prevention but target the pathway differently: Aimovig (erenumab) blocks the CGRP receptor itself, while Ajovy (fremanezumab) and Emgality (galcanezumab) bind to the CGRP ligand before it reaches the receptor. Aimovig and Emgality are dosed monthly; Ajovy offers both a monthly 225 mg dose and a quarterly 675 mg dose (three injections at once). Emgality also carries an additional FDA approval for episodic cluster headache that Aimovig and Ajovy do not have.
